02Jan 2024
Early infliximab trough levels in paediatric IBD patients predict sustained remission

Early infliximab trough levels in paediatric IBD patients predict sustained remission

In pediatric inflammatory bowel disease patients receiving standard infliximab treatment, the study aimed to determine whether trough levels at week 6 or week 14 could predict sustained remission. Analyzing electronic healthcare data from 70 patients, the study found that the median infliximab level at week 14 significantly correlated with sustained remission (7.7 mg/L versus 3.8 mg/L; p = 0.006). The receiver operating characteristic curves indicated a predictive accuracy 0.75 (95% CI 0.60–0.90) at week 14. Target trough levels for weeks 6 and 14 were determined as ⩾13.2 and ⩾6.9 mg/L, respectively, supporting week 14 measurements for optimal prediction of sustained remission.

  • #gastroenterology

Like

Save

Share